ACOBIOM is a biotechnology company specialized in the discovery of genomic or transcriptomic biomarkers and the development of innovative diagnostics. Thanks to its unique scientific expertise in the analysis of gene expression in blood cells and whole blood, ACOBIOM is positioned in the field of Precision Medicine and in the development of diagnostics to help in the choice of the most effective or the most adapted treatment to the biological (phenotypic) profile of patients.

Contact

busdev@acobiom.com

Address

1682 Rue de la Valsière – Cap Delta – Biopole Euromedecine II – 34790 GRABELS – FRANCE

Website

acobiom.com

Targeted indications : Breast cancer, Lung cancer, Gastrointestinal cancers

L’article ACOBIOM est apparu en premier sur OncoSTART.

ADELIS Technologies (ex Picometrics) is an analytical instrumentation company. ADELIS has developed proprietary analysis platform (BIABOOSTER) enabling to concentrate, fractionate and separate free-circulating-DNA directly from plasma samples with unrivalled sensitivity to address cancer treatment and relapse monitoring liquid biopsy applications.

Contact

jcgarcia@adelis-tech.com

Address

310 RUE LOUIS PASTEUR 34790 GRABELS

Contact

www.adelis-tech.com

Targeted indications : Lung cancer, Colorectal cancer, Stomach cancer, Liver cancer, Gastrointestinal cancers, Hematologic cancer

L’article ADELIS est apparu en premier sur OncoSTART.

Advanced BioDesign is a French biotechnology company that is developing a new innovative targeted therapy against resistant cancers, with a first indication in acute myeloid leukemia (AML). Its main anticancer compound, DIMATE (ABD-3001), is a first-in-class suicide inhibitor of aldehyde dehydrogenases 1 & 3 (ALDH1 & 3). By inhibiting this enzyme, ABD-3001 causes cancer cell apoptosis without damaging healthy cells.

Contact

ismail.ceylan@a-biodesign.com

Address

655 ALLEE DES PARCS – BATIMENT D – 69800 SAINT-PRIEST

Website

www.a-biodesign.com

Targeted indications : Cancer du sein, Cancer du poumon, Cancer de la peau, Cancer hématologique

L’article Advanced BioDesign est apparu en premier sur OncoSTART.

Dyameo offers an instantaneous and new approach for cancer cells detection. Located at the end of a few millimetres diameter optical fiber, our tool facilitates the diagnosis by analysing the patient’s tissue in real time. Dyameo’s technology is based on a platform of innovative patented biosensors allowing the ultra fast detection of biomarkers or other molecules. The first targeted application is the delimitation of the resection margins during oncology surgeries.

Contact

contact@dyameo.com

Address

1 Avenue D’ESTER 87280 LIMOGES

Website

www.dyameo.com

Targeted indications : Lung cancer, Head and neck cancers, Skin cancer

L’article Dyameo est apparu en premier sur OncoSTART.

EverImmune is a spin-off biotech. Cie from Gustave Roussy Transfert, created in 2016 and devoted to treating cancer patients with live biotherapeutic products (LBP) i.e immunogenic commensals that are called “Oncobax®” for oral adjuvants to anticancer immunotherapy. EverImmune harness the gut microbiota for the development of a revolutionary theranostic approach combining diagnostic and therapeutic technologies that will ensure the benefit of ICBs in cancer patients.

Contact

valerie.zitvogel@gmail.com

Address

39 RUE CAMILLE DESMOULINS, 94800 VILLEJUIF

Targeted indications : Lung cancer

L’article EverImmune est apparu en premier sur OncoSTART.

Contact email : elena.khomyakova@exosome-analytics.com

L’article Exosome Analytics est apparu en premier sur OncoSTART.

Explicyte immuno-oncology offers preclinical contract research services for cancer immunotherapy drug discovery. Our preclinical CRO services range from (i) cell-based assays – for in vitro characterization of new anti-cancer immune modulators – (ii) in vivo proof-of-concept studies in validated syngeneic mouse tumor models (ii) to biomarker analysis through cutting-edge technologies such as digital histology, multispectral imaging as well as digital spatial profiling.

Contact

contact@explicyte.com

Address

229 Cours de l’Argonne, 33000 Bordeaux

Website

www.explicyte.com

Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article EXPLICYTE est apparu en premier sur OncoSTART.

HalioDx is an immuno-oncology diagnostic company providing first-in-class diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology. Immunoscore® assay family, is available internationally as a regulatory compliant tests to guide day to day oncologists’ decisions and help Biopharma in their clinical developments. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression.

Address

Luminy Biotech Entreprises 163 Avenue de Luminy 13288 Marseille Cedex 9

Website

www.haliodx.com

Targeted indications : Cancer du poumon, Cancer colorectal

L’article HalioDx est apparu en premier sur OncoSTART.

CEO : François Auvray

contact@hyprview.com

www.hyprview.com

L’article HyprView est apparu en premier sur OncoSTART.

The company ID-Solutions, created in 2016 and based near Montpellier, develops and produces a complete solution for the diagnosis of COVID-19 (RT-PCR test) as well as innovative and standardized tools for the diagnosis by digital PCR in oncology. on circulating DNA and tumor DNA.

Contact

info@id-solutions.fr

Address

310, rue Louis Pasteur 34790 GRABELS

Website

www.id-solutions.fr

Targeted innovation : Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Brain cancer, Skin cancer, Lymphoma, Myeloma

L’article ID SOLUTIONS est apparu en premier sur OncoSTART.